Discovery of cryptophycin-1 and BCN-183577: Examples of strategies and problems in the detection of antitumor activity in mice

Investigational New Drugs

Volumn 15, Issue 3, 1997, Pages 207-218

  Corbett, Thomas H ^a   Valeriote, Frederick A ^a   Demchik, Lisa ^a   Lowichik, Nancy ^a   Polin, Lisa ^a   Panchapor, Chiab ^a   Pugh, Susan ^a   White, Kathryn ^a   Kushner, Juiwanna ^a   Rake, James ^b   Wentland, Mark ^c   Golakoti, Trimurtulu ^d   Hetzel, Cari ^d   Ogino, Junichi ^d   Patterson, Gregory ^d   Moore, Richard ^d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sanofi Winthrop Inc   (United States)

^c Research Rensselaer Polytechnic Institute   (United States)

^d UNIVERSITY OF HAWAII   (United States)

Author keywords

Cryptophycin 1; Discovery strategies; Preclinical

Indexed keywords

ANTINEOPLASTIC AGENT; BCN 183577; CRYPTOPHICIN 1; THIOXANTHENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CELL MEDIATED CYTOTOXICITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG SCREENING; DRUG SOLUBILITY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; MALE; MICE; NEOPLASMS, EXPERIMENTAL; PEPTIDES, CYCLIC; THIOXANTHENES; TUMOR CELLS, CULTURED;

EID: 9844224483     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005875015011     Document Type: Review

References (15)

1. Corbett TH, Valeriote FA, Polin L, et al: Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion-assay. Cytotoxic Anticancer Drugs: Models and concepts for drug discovery and development, FA Valeriote, TH Corbett and LH Baker (eds), Kluwer Academic Publishers, p 33-87, Boston/Dordrecht, London, 1992.
2. Corbett T, Valeriote F, LoRusso P, et al: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacogn, Supp 33: 102-122, 1995.
3. Corbett T, Valeriote F, Baker L: Is the P388 murine tumor no longer adequate as a drug discovery model: Invest New Drugs 5: 3-20, 1987.
4. Corbett TH, Valeriote FA: Rodent Models in Experimental Chemotherapy, The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, RF Kallman (ed), Pergamon Press, Chapt 50, pp 233-247, 1987.
5. Corbett T, Valeriote F, LoRusso P, et al: Use of rodent solid tumors for drug discovery. In: Cancer Drug Discovery, Chapter 5, BA Teicher (ed), Humana Press Inc, 1997.
6. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Tumor induction relationships in development of transplantable cancers of the colon in mice of chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439, 1975.
7. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40(5): 2660-2690, 1977.
8. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717-726, 1984.
9. Golakoti T, Ohtani I, Patterson GML, Moore RE, Corbett TH, Valeriote FA, Demchik L: Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp Strain GSV 224. J Am Chem Soc 116: 4729-4737, 1994.
10. Golakoti T, Ogino J, Heltzel CE, Husebo TL, Jensen CM, Larsen LK, Patterson GML, Moore RE, Mooberry SL, Corbett TH, Valeriote FA: Structure determination, conformational analysis, chemical stability studies and antitumor evaluation of the cryptophycins. Isolation of eighteen new analogs from Nostoc sp. Strain GSV 224. J Am Chem Society 117(49): 12030-12049, 1995.
11. Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Kushner J, Jones J, Jones L, Foster B, Wiegand R, Lisow L, Golakoti T, Heltzel C, Ogino J, Patterson G, Moore R: Preclinical anticancer activity of cryptophycin-8. J Exp Ther Oncol 1: 95-108, 1996.
12. Corbett T, Valeriote F, Baker L, et al: Antitumor activity of N-[[1-[[2-(Diethylamino)ethyl]amino]-9-oxo-9H-Thioxanthen-4-Y]methyl] methanesulfonamide (WIN33377) and analogs: Expert opinion on Investigational Drugs 3(12): 1281-1292, 1994.
13. Horwitz JP, Massova I, Wiese TE, Bessler BH, Corbett TH: Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-ones against pancreatic ductal carcinoma. J Med Chem 37: 781-876, 1994.
14. Wentland MP, Perni RB, Powles RG, Hlavac AG, Mattes KC, Corbett TH, Coughlin SA, Rake JB: Anti-solid tumor efficacy and preparation of N-[[1-[[2-(Diethylamino)Ethyl]Amino]-9-OXO-9H-Thioxanthen-4-YL] Methyl] Methanesulonamide (WIN33377) and related derivatives. Bioorg Med Chem Lett 4(4): 609-614, 1994.
15. Schabel JR FM, Griswold Jr DP, Corbett TH, Laster Jr WR, Mayo JC, Lloyd HH: Testing therapeutic hypotheses in mice and man. Observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated on potential clinical utility for treatment of advanced solid tumors of man. In: Cancer Drug Development. Part B. Methods in Cancer Research, Vol 17, H Busch and V DeVita Jr (eds), Academic Press Inc, New York, pp 3-51, 1979.